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Edited by Gianni CesareniAbstract Somatic angiotensin I-converting enzyme (s-ACE)
plays a central role in blood pressure regulation and has been
the target of most antihypertensive drugs. A displacement iso-
thermal titration calorimetry method has been used to accurately
determine the binding constant of three strong s-ACE inhibitors.
Under the experimental conditions studied in this work, the rel-
ative potency of the inhibitors was determined to be enala-
prilat > lisinopril > captopril. We analyze the thermodynamic
behaviour of the binding process using the new structural infor-
mation provided by the ACE structures, as well as the conforma-
tional changes that occur upon binding.
 2007 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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During the mid-1950s the role of angiotensin I-converting
enzyme (ACE; EC.3.4.15.1) in the regulation of blood pressure
stimulated the interest of its study due to the use of ACE inhib-
itors as antihypertensive agents [1]. Captopril was the ﬁrst or-
ally active antihypertensive inhibitor to be developed and was
among the earliest successes of the revolutionary concept of
structure-based drug design [2]. Many highly potent ACE
inhibitors such as enalaprilat, lisinopril, ramipril, quinapril,
perindopril and benazepril have subsequently been developed
over the last two decades [3,4]. That all of them are among
the most used drugs for the hypertension treatment and pro-
vide an example of successful drug design in silico. As ACE
structures have only become recently available, these drugs
were designed using the active site of other zinc dependent
dipeptidyl carboxypeptidases of known structure. However,
the target of these drugs, the somatic ACE (s-ACE), has been
proved to be a complex enzyme with two homologous catalytic
domains arising from gene duplication [5]. Despite the twoAbbreviations: ACE, angiotensin I-converting enzyme; s-ACE, somatic
angiotensin I-converting enzyme; t-ACE, testicular angiotensin I-
converting enzyme; ACE2, angiotensin-converting enzyme-2; ASA,
accessible surface areas; FAPGG, 2-furanacryloyl-L-phenylalanylgly-
cylglycine; enalaprilat, (S)-1-[N-(1-carboxy-3-phenylpropyl)-L-alanyl]-
L-proline; Captopril, D-[3-mercapto-2-methylpropanoyl]-L-proline;
lisinopril, Na-[(S)-1-carboxy-3-phenyl]-L-lysil-L-proline; L-Asp-L-Phe,
L-aspartyl-L-phenylalanine; ITC, isothermal titration calorimetry
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doi:10.1016/j.febslet.2007.06.048domains, called N- and C-domain, sharing approximately
60% sequence identity, they have distinctive physicochemical
and functional properties. Another shorter ACE, the testis
ACE (t-ACE), has been reported to be tissue-speciﬁc. This
ACE form shares higher homology with the C-domain of
s-ACE. The crystal structure of the human t-ACE has been
determined as the unbound form and as a complex with lisin-
opril [6], captopril and enalaprilat [7]. In addition, the struc-
tures of the N-domain of human s-ACE in the presence and
absence of lisinopril have become available [8]. The analyses
of these structures reveal that the three inhibitors directly
interact with the catalytic Zn2+ ion in the active site of the
enzyme through the thiol group of captopril and the carboxyl-
ate groups of enalaprilat and lisinopril. These results show that
both domains are potential binding sites for the substrate and
inhibitors. However, recent results support a stoichiometry of
only 1 mol of inhibitor per mol of monomer of s-ACE [9,10].
These results and the evidence of conformational changes
in the structure of the homologous angiotensin-converting
enzyme-2 (ACE2) [11] reveal that the enzymatic mechanism
of s-ACE is a complex process and that the interactions
between the N- and C-domain cannot be ruled out. Addition-
ally, the role played by the chloride ions in the regulation of
the enzyme activity is a subject of increasing interest [12].
A better knowledge of the interaction at molecular level of
ACE inhibitors will help in the design of new drugs for high
blood pressure treatment. Isothermal titration calorimetry
(ITC) has been widely used to obtain thermodynamic informa-
tion related to the binding process in biological macromole-
cules [13]. It has been proposed to be an important tool in
understanding the correlation between structure and thermo-
dynamic parameters [14]. However, the determination of the
thermodynamic parameters that drive the binding of these
inhibitors to ACE is limited by the high value of their binding
constants [15]. In order to estimate the binding constant from a
titration experiment the ratio between the binding constant
and the protein concentration must be in 1–1000 range, prefer-
ably between 10 and 100 [16]. Thus, any direct measurement of
these large binding constants requires very low protein concen-
trations, which is translated into a heat signal close to the
detection limit. Sigurskjold [17] described a displacement
method that can be applied to the determination of large bind-
ing constants. The method requires a competitive inhibitor
with a known binding constant. In the present study, the deter-
mination of the binding constant of the weak ACE inhibitor
L-aspartyl-L-phenylalanine (L-Asp-L-Phe) to s-ACE by means
of ITC is reported. Using the method developed by Sigur-
skjold, we have determined the binding constant of the strong
inhibitors lisinopril, captopril and enalaprilat to s-ACE fromblished by Elsevier B.V. All rights reserved.
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the new structural information provided by the recent ACE
structures. These analysis provide an explanation of the ob-
served thermodynamic behaviour, which consists of an entro-
pically driven binding process.2. Materials and methods
2.1. Materials
Concanavalin A-Sepharose and epoxy activated Sepharose 6B were
purchased from Amersham Biosciences. HEPES and cacodylate were
purchased from Sigma. Enalaprilat was generously provided from
Merck. All other chemicals were of reagent grade and obtained locally.
Lisinopril was coupled to epoxy activated Sepharose 6B as described
elsewhere [18]. s-ACE was puriﬁed from pig lungs using a two-step
aﬃnity chromatography with concanavalin A-Sepharose followed by
lisinopril Sepharose 6B as described previously [18]. s-ACE concentra-
tions were determined using a molar absorption coeﬃcient of
2.2 · 105 M1 cm1 at 280 nm [18].
2.2. Enzyme activity assay
s-ACE activity was assayed using 2-furanacryloyl-L-phenylalanyl-
glycylglycine (FAPGG) as substrate as described previously [18].
Brieﬂy, the protein was buﬀered at pH 7.5 with 50 mM HEPES,
0.3 M NaCl and 10 lM ZnCl2. Seven hundred and seventy microliters
of buﬀer were mixed with 200 lL of 0.5 mM FAPGG. The reaction
was initiated by adding 30 lL of enzyme solution containing 1–3 lg
of protein to a cuvette thermostatted previously at 25 C. The absor-
bance decrease at 334 nm was monitored for two minutes and the ini-
tial velocities were determined. One unit of activity is deﬁned as the
amount of s-ACE that produces a DA334/min of 1.0. Puriﬁed s-
ACE has an activity of 35–37 U/mg. Activity assays at a constant
inhibitor concentration and varying substrate concentrations were
done in order to determine the inhibition constant.
2.3. Isothermal titration calorimetry
ITC experiments were performed using a MCS microcalorimeter
from Microcal Inc. (Northampton, MA, USA). This instrument has
been described in detail by Wiseman et al. [16]. The reference cell
was ﬁlled with water, and the instrument was calibrated using standard
electrical pulses. A circulating water bath was used to stabilize the tem-
perature. The instrument was allowed to equilibrate overnight. All
solutions were thoroughly degassed by stirring under vacuum before
use. Solutions of s-ACE were titrated with 10 identical 10 ll injections
at 6 min-intervals. The injection syringe, on which a paddle is
mounted, stirred the solutions at 300 rpm, ensuring immediate mixing.
Concentrations of the protein used for the titrations were in the range
of 3.5–16.4 lM, while concentrations of the inhibitors were 0.6–3.0
mM (L-Asp-L-Phe) and 0.2–0.5 mM (lisinopril, captopril and enala-
prilat). All the experiments in this study were conducted at a NaCl con-
centration of 300 mM and in at least two diﬀerent buﬀers. Dilution
experiments were performed by identical injections of s-ACE inhibitor
into the cell containing only buﬀer. The peaks of the thermograms
were integrated and the heat produced by the binding reaction was cal-
culated as the diﬀerence between the reaction heat and the correspond-
ing dilution heat. The resulting binding isotherms were analysed by
non-linear least-squares ﬁttings to a model corresponding to a single
set of identical sites, according to the equation:
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where Q is the total heat, K is the binding constant, DH is the change in
the enthalpy due to the binding process, n the number of sites, V0 the
active cell volume, Pt is the total concentration of the enzyme in V0,
and It is the total concentration of the inhibitor. Data were analyzed
with the ORIGIN 5 software (MICROCAL). Enzyme activity was
checked before and after the calorimetric experiment. The s-ACE–
inhibitor complex showed less than 1% activity. pH values of the buf-
fers, inhibitors and protein solutions were checked before and after the
experiment.Direct ITC titrations were made to determine binding enthalpy and
binding constants for L-Asp-L-Phe. Binding constants for the strong
inhibitors, captopril, lisinopril and enalaprilat, were measured by the
displacement method proposed by Sigurskjold [17]. Brieﬂy, for each
displacement experiment a solution of s-ACE was ﬁrst titrated until
saturation with the weak inhibitor L-Asp-L-Phe. Then, the injection
syringe was cleaned and reﬁlled with a solution of the strong inhibitor
to perform a second titration. The results of these experiments were
analyzed according to the method proposed by Sigurskjold with an
ORIGIN function ﬁle kindly provided by this author.
2.4. Accessible surface areas
Accessible surface areas (ASA) were calculated with the program
NACCESS [19] by using a 1.4 A˚ probe radius and 0.05 A˚ slice width.
Calculated values of heat capacity changes (DCp,cal) were derived
according to Spolar and Record [20]:
DCp;cal ¼ ð1:34  DASAnpÞ  ð0:59  DASApÞ J=K mol ð2Þ
where DASAnp and DASAp are the respective changes in water-acces-
sible non-polar (np) and polar (p) surface area in A˚2. ASA changes
upon the binding of the inhibitor were calculated using the equation:
DASA ¼ ASAACE-Inh  ðASAACE þASAInhÞ A˚2 ð3Þ
where ASAACE-Inh, ASAACE and ASAInh represent the water-accessi-
ble surface area for the s-ACE:inhibitor complex, and protein and
inhibitor alone respectively.3. Results
3.1. Binding of L-Asp-L-Phe to s-ACE
With the aim of comparing the value of the binding constant
obtained by means of ITC measurements, activity assays at
constant inhibitor concentration and varying substrate concen-
trations were conducted in order to determine the inhibition
constant of L-Asp-L-Phe for the pig lung s-ACE. Assuming
competitive inhibition:
KM ¼ KM0 1þ ½lAsp l PheKI
 
ð4Þ
where KM0 is the Michaelis constant in the absence of inhibi-
tor. A KM0 value of 2.4 · 104 M and KI = 8.9 · 105 M were
obtained by plotting KM versus [L-Asp-L-Phe] and the aﬃnity
constant determined by activity assays was 1.1 · 104 M1.
Fig. 1 shows a representative titration of s-ACE with L-Asp-
L-Phe. Experimental data were ﬁtted to Eq. (1) and only one
site per s-ACE molecule was obtained. Titrations in two diﬀer-
ent buﬀers, HEPES and Cacodylate, were conducted to deter-
mine the number of protons exchanged during the binding
process. The number of protons released in the titration of
L-Asp-L-Phe at pH 7 is 0.7. ITC titration experiments were
carried out at temperatures in the range of 15–25 C to deter-
mine the DCp value. Table 1 shows the values of the thermody-
namic parameters obtained from the analysis of the data.
3.2. Binding constants of lisinopril, captopril and enalaprilat
determined by displacement measurement
Fig. 2 shows the binding isotherm corresponding to the titra-
tion of s-ACE saturated with L-Asp-L-Phe with a solution of
enalaprilat at pH 7 and 16 C. Similar experiments were car-
ried out using captopril and lisinopril. The results are shown
in Table 2. It can be seen that as temperature raise, DG
becomes more negative and consequently K increases accord-
ing to the endothermic nature of the binding process. At
pH 7 and the range of the studied temperatures, the relative
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Fig. 1. Calorimetric titration proﬁle of the binding of L-Asp-L-Phe to
s-ACE. The experiment was performed at 20.8 C. The conditions
were: 10.76 lM s-ACE and 3 mM L-Asp-L-Phe in 50 mM HEPES
buﬀer, pH 7, containing 0.3 M NaCl and 50 lM Zn(CH3COO)2.
Upper panel shows the raw data associated with the injection of L-
Asp-L-Phe into the sample cell containing s-ACE. Lower panel
represents the integrated peak areas per mol of ligand corrected for
heats of dilution. The solid line through the data represents the line of
best ﬁt obtained using ORIGIN 5 software to Eq. (1).
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Fig. 2. Displacement calorimetric titration of s-ACE bound to L-Asp-
L-Phe with enalaprilat at pH 7 and 16.3 C. Upper panel shows the
thermogram corresponding to 20 injections of enalaprilat 0.33 mM
into the sample cell containing s-ACE 12.6 lM and L-Asp-L-Phe
0.30 mM. Lower panel shows integrated heat per mole of enalaprilat
after subtraction of dilution heats. The solid line through the data
represents the line of best ﬁt obtained using ORIGIN 5 software to
Eq. (1).
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topril. The binding isotherm was analyzed taking into account
a single type of sites and the resulting stoichiometry was 1 mol
of inhibitor by mol of s-ACE monomer.
Entropy changes for the binding of captopril, lisinopril, and
enalaprilat to s-ACE were determined from the equation
DG = DH  TDS and are collected in Table 2. The thermody-
namic analysis of the change of entropy due to the binding
process proposed by Spolar and Record [20] has been applied
to discriminate between rigid body associations and those
involving coupled conformational changes. Brieﬂy, for protein
ligand association at the characteristic temperature TS, where
the net entropy change is zero, the following equation is ful-
ﬁlled:
DS ¼ 0 ¼ DSHEðT SÞ þ DSrt þ DSother ð5Þ
where DSHE (TS) is the contribution to the observed change of
the entropy due to the hydrophobic eﬀect, DSrt is the unfavor-
able entropic term arising from the reduction in the availableTable 1
Thermodynamics analysis of the interaction between L-Asp-L-Phe and s-AC
Temperature (K) Buﬀer DHT (kJ/mol) DHB (kJ/mo
289.3 HEPES 28.7 ± 1.2 14.5 ± 1.0
Cacodylate 13.6 ± 0.8
293.6 HEPES 25.4 ± 1.5 11.2 ± 1.0
Cacodylate 10.3 ± 0.5
298.0 HEPES 19.1 ± 1.0 4.9 ± 0.7
Cacodylate 4.0 ± 0.3rotational and translational degrees of freedom of the protein
and ligand on complexation, and DSother represents any other
diﬀerent contribution to the change of entropy from those
mentioned before, that mainly involves the eﬀects of a confor-
mational change coupled to the binding process. The estimated
TS values for the binding of the three inhibitors were calculated
from entropy changes at 25 C and assuming a constant value
of the DCp,
DSðT SÞ ¼ 0 ¼ DSð25 CÞ þ DCp lnðT S=298:15Þ ð6Þ
where TS is considered in Kelvin. DSHE is related to the
value of the DCp and it can be calculated from the following
equation:
DSHE ¼ 1:35DCp lnðT S=386Þ ð7Þ
DSrt can be taken as 210 J/K mol [21] and DSother values were
calculated for the three inhibitors. Results are shown in Table
2. Calculated heat capacity values (DCp,calc) from the changes
in water-accessible non-polar and polar surface area are shown
in Table 3.E
l) DG (kJ/mol) DS (kJ/K mol) DCP (kJ/K mol)
22.6 ± 0.4 0.13 ± 0.01
22.3 ± 0.2 0.12 ± 0.01 1.1 ± 0.2
22.5 ± 0.2 0.09 ± 0.01
Table 2
Thermodynamic parameters and constants for the binding of enalaprilat, captopril and lisinopril to s-ACE
Inhibitor T (K) Buﬀer DHT (kJ/mol) DHb
a (kJ/mol) DG (kJ/mol) DS (J/K mol) DSHE
b
(J/K mol)
DSother
b
(J/K mol)
K (M1)
Enalaprilat 289.4 HEPES 65.1 ± 1.2 45.1 ± 1.0 47.9 ± 1.9 321.4 ± 3.1
Cacodylate 42.9 ± 0.8
293.8 HEPES 54.1 ± 0.9 32.9 ± 1.1 49.2 ± 1.9 279.4 ± 2.7 525.3 315.3 6.2 · 108 ± 0.5 · 108
Cacodylate 32.0 ± 1.1
298.2 HEPES 45.3 ± 1.2 23.1 ± 0.9 50.2 ± 2.0 245.9 ± 3.7
Cacodylate 22.2 ± 0.6
Lisinopril 289.4 HEPES 69.9 ± 0.9 48.8 ± 0.6 44.7 ± 2.2 323.5 ± 5.5
Cacodylate 45.2 ± 0.3
293.9 HEPES 55.2 ± 0.8 34.1 ± 0.7 46.0 ± 2.2 273.3 ± 5.1 496.3 286.3 1.9 · 108 ± 0.2 · 108
Cacodylate 32.3 ± 0.4
298.4 HEPES 49.8 ± 0.8 27.2 ± 0.6 47.3 ± 2.2 250.0 ± 5.4
Cacodylate 25.1 ± 0.4
Captopril 289.9 HEPES 45.3 ± 0.8 38.9 ± 0.8 42.8 ± 1.5 282.7 ± 2.4
Cacodylate 35.4 ± 0.7
293.8 HEPES 40.1 ± 1.0 31.7 ± 0.9 44.0 ± 1.5 258.4 ± 2.1 412.1 202.1 7.5 · 107 ± 0.5 · 107
Cacodylate 31.7 ± 0.6
298.5 HEPES 31.0 ± 0.5 25.4 ± 0.5 45.0 ± 1.6 236.2 ± 3.7
Cacodylate 22.9 ± 0.4
aThese values were obtained considering the ionization values for the buﬀers reported for HEPES (DHion = 21.01 kJ/mol, DCp,ion = 48.74 J/K mol)
and Cacodylate (DHion = 1.96 kJ/mol, DCp,ion=-78.49 J/K mol). Experiments were conducted in the presence of 0.3 M NaCl and 0.05 mM Zinc
Acetate.
bTS (K): enalaprilat 329.1, lisinopril 331.0 and captopril 332.8.
Table 3
Heat capacities calculations from C-domain ACE X-ray coordinates
DASAnp
(A˚2)
DASAp
(A˚2)
DCp,calc
(J/mol K)a
DCp,obs
(J/K mol)
Lisinopril complex (a) 240 41 297 2400
Enalapril complex (b) 221 49 286 2400
Captopril complex (c) 174 6 231 2100
Brookhaven Protein Database (PDB) C-domain ACE structures: (a)
lisinopril code 1o86, (b) enalaprilat code 1uze, (c) captopril code 1uzf.
aDCp,calc calculated using the Spolar and Record approach [33]:
DCp,calc = 1.34 · DASAnp 0.59 · DASAp (J/K mol).
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The binding constants of three strong inhibitors of s-ACE
have been determined by a thermodynamic technique using
the displacement method proposed by Sigurskjold [17]. It is
based in the binding of a relatively weak ligand and the subse-
quent displacement by a higher aﬃnity competitive ligand.
Several years ago L-Asp-L-Phe, a metabolite of aspartame,
was reported to inhibit s-ACE [22] with a KI constant of
11 lM for the enzyme partially puriﬁed from rabbit lung
[23]. In our case the protein has been fully puriﬁed from pig
lung and we have checked the inhibitor constant by enzymatic
measurement obtaining a KI value of 89 lM under the same
experimental conditions than those reported by Grobelny
and Galardy [22]. The aﬃnity constant obtained by means of
ITC at 25 C has a value of 9.2 · 103 ± 0.4 · 103 M1 which
agrees, within the error, with the value of the corresponding
constant obtained by enzymatic measurements. In the range
of temperatures studied here, the binding of L-Asp-L-Phe to
s-ACE is endothermic and the enthalpy decreases at higher
temperatures, while the binding constant is much less aﬀectedby temperature changes as a consequence of an enthalpy–en-
tropy compensation. This behaviour is commonly observed
in ligand–protein interactions [24]. Although s-ACE has two
potential binding sites for the substrate/inhibitor, only one site
by enzyme monomer was obtained. This result agrees with
those previously reported for the study of the binding of cap-
topril, enalaprilat and lisinopril to s-ACE [9] and also with
those reported by Binevski et al. [10]. Moreover, Skirgello
et al. [25] reveal by means of enzymatic measurements that
the kinetic analysis of the simultaneous hydrolysis of two sub-
strates by s-ACE demonstrated a competition of these sub-
strates for binding to the s-ACE molecule and, as
consequence, the binding of a substrate at a unique active site
makes the other one unavailable for either the same or a diﬀer-
ent substrate.
The thermodynamic determinations of the inhibition con-
stant of the three potent inhibitors captopril, enalaprilat and
lisinopril show that enalaprilat is the strongest inhibitor with
an aﬃnity constant of 6.2 · 108 M1 whilst the weakest one,
captopril, has an aﬃnity constant one order of magnitude
smaller, 7.5 · 107 M1. Several authors have reported diﬀerent
aﬃnity and selectivity to the N- and C-domains of s-ACE
[26–28] for its inhibitors. Wei et al. [15] show that at a concen-
tration of 300 mM NaCl the relative potency of the three
inhibitors for the C-domain of s-ACE was lisinopril (4.2 · 109
M1) > enalaprilat (1.6 · 109 M1) > captopril (7.1 · 108 M1)
and for the N-domain captopril (1.1 · 109 M1) > enalaprilat
(3.8 · 108 M1) > lisinopril (2.3 · 108 M1). However, for the
whole s-ACE, the relative potency for lisinopril, enalaprilat
and captopril have similar values to those reported for the
C-domain, with constant values of 2.6 · 109, 1.53 · 109 and
7.69 · 108 M1, respectively. These values were obtained by
enzymatic measurements at 37 C and pH 8.3 and they are
one order of magnitude higher than the value obtained by
means of the displacement method using ITC. Due to the
Fig. 3. Superposition of the active site and chloride site II in the
unbound (blue, PDB code 2C6F) and lisinopril bound human N-ACE
(yellow, PDB code 2C6N). Residues 5 A˚ around chloride ion are
shown.
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ing constant will become higher as the temperature increases.
In addition, the ITC experiments were carried out at pH 7
and a pH dependence has been reported for the enzymatic
activity of s-ACE due to several ionizable groups present in
the active site [29]. Moreover, the nature of the interactions
established at the binding site for the inhibitors enalaprilat
and lisinopril is very similar but not identical. Both inhibitors
interact with the zinc atom in the active site through the car-
boxyl group with a pKa value near to 3 [30]. Besides, lisinopril
contains a lysine which has a pKa value about 7 and interacts
with the subsite S01 and could be responsible of the observed
changes in the aﬃnity constant as the pH increase. In this
way, the lysine moiety of the lisinopril is interacting with
Glu162 in the C-domain (human t-ACE structure) and this
interaction must be weaker as the lysine becomes unproto-
nated at pH values above 7. A diﬀerent picture could be drawn
for the N-domain where Glu162 is replaced by Asp140, but the
longer distance between this residue and the lysil group makes
this interaction weaker and may contribute to the lower aﬃn-
ity of this domain for lisinopril.
The enthalpy values measured by the displacement method
of Sigurskjold [17] are similar to those reported previously
by direct ITC titrations for the three inhibitors [9]. As dis-
cussed previously, the three inhibitors show almost the same
positive enthalpy change upon binding and enthalpically
favorable interactions could play a role in the speciﬁcity of
the binding process. Their contribution to the energy of bind-
ing is overcome by the hydrophobic contribution. A large con-
tribution of entropy is indicative of such hydrophobic eﬀect.
Moreover, to discriminate between rigid body associations
and those involving coupled conformational changes we used
the Spolar and Record approach [20] to analyze the entropy
change. When any conformational changes take place DSother
becomes negative (values are given in Table 2), as it happens
for the three studied inhibitors. This means that conforma-
tional changes can not be ruled out. The ACE2 structure, a
homolog of ACE, has been solved in two diﬀerent conforma-
tions [31]. A hinge mechanism was proposed to switch from
the open-unligated ACE2 to the close-ligated ACE2 and,
based on modeling studies, it has been suggested to play an
important role in s-ACE as well [32]. The closing of the active
site would result in the association of numerous residues that
would otherwise be bound to ordered solvent molecules when
the protein is in an open conformation.
The large DCp,assoc obtained experimentally indicate that the
binding of the inhibitors to s-ACE is not a rigid body binding.
Thus, heat capacity changes can be estimated on the basis of
X-ray structures using also the Spolar and Record approach
[33]. The structure of the whole s-ACE has not been described
yet, however the structures of C-domain (human t-ACE) are
available as unbound and complexed with the three strong
inhibitors (enalaprilat, lisinopril and captopril). Since only
one mol of inhibitor is bound by one mol of s-ACE, we used
the structure of the C-domain bound to the three inhibitors
structure to calculate the changes of polar and non-polar
ASA upon binding. In the case of a rigid body binding the con-
tribution of the N-domain to the change in non-polar and po-
lar ASA can be considered constant. The comparisons between
the experimental and calculated changes of the heat capacities
values (Table 3) show a wide divergence for the three inhibi-
tors. These discrepancies can be attributed to conformationalchanges. Moreover, the large negative heat capacity indicates
a decreased exposure of hydrophobic surface, such as it occurs
in the burial of surface within a protein interface. This confor-
mational change can account for the strong negative coopera-
tivity between the two sites which result in the binding to a
single site [9,10].
The crystallographic structures of C-domain (t-ACE) and
N-domain of s-ACE show the presence of chloride ions bound
to the enzyme. In the case of C-domain two sites have been re-
ported: chloride I and chloride II, respectively. Although chlo-
ride II site is placed near the active site, no direct interactions
between the chloride atom and the inhibitors are observed. The
chloride II site is also observed in the N-domain structure but
not the chloride I site. ACE activity has been reported to be
dependent on the chloride concentration and the N-domain
is activated at lower concentration and to a lesser extent than
the C-domain [26]. ITC experiments were performed at high
chloride concentration where full activation of the s-ACE
takes place. The dependence on chloride concentration has
been also reported for the ACE2 enzymatic activity [11], but
in this case only the chloride I site is occupied and the a-helices
surrounding this chloride site shows a signiﬁcant displacement
upon inhibitor binding. In the N-domain of s-ACE, Arg500 is
bound to both the chloride ion and Glu389, which is coordi-
nating the zinc atom in the active site, and upon inhibitor bind-
ing the distance between Arg500 and Glu389 is reduced from
4.4 A˚ to 3.5 A˚ (Fig. 3). Therefore, upon inhibitor binding,
ACE structures show some changes at the chloride sites that
might play an important role in the ACE activation.
The chloride concentration dependence of the enzymatic
activity of the C- and N-domain, together with the weaker
binding inhibitor constant found for the captopril, allow us
to propose that the inhibitors in this study bind to the C-do-
main of s-ACE. This observation also agrees with the fact that
kcat determined for s-ACE is not signiﬁcantly diﬀerent from the
one determined for t-ACE, suggesting that C-domain is the
principal angiotensin-converting domain [34]. Furthermore,
the expression of modiﬁed ACE domains CNdom-ACE and
CCdom-ACE [35] show negative cooperativity between the
N and C-domain in both s-ACE and CNdom-ACE, but the
CCdom-ACE resulted in either additive catalytic activity or
positive cooperativity. Consequently, a negative regulatory ef-
fect on catalytic activity of two-domain enzymes is proposed
for the N-domain. Moreover, in order to allow interdomain
cooperativity, a ﬂexible interdomain bridge that permits close
3454 M. Andu´jar-Sa´nchez et al. / FEBS Letters 581 (2007) 3449–3454contact between the two domains is required. Unfortunately,
no structure of the complete s-ACE is available and there is
no information relating to how the conformational changes
are transferred between the N- and C-domains. A better
knowledge of thermodynamic parameters of the binding pro-
cess of ACE inhibitors and how these conformational changes
take place could help in the rational design of new and more
eﬀective drugs for the treatment of hypertension.
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